Asset
MUPADOLIMAB
Corvus Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03454451 | phase1 | completed | 2018-04-25 | 2022-12-28 | Corvus Pharmaceuticals, Inc. | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
| NCT04734873 | phase3 | terminated | 2021-02-25 | 2021-08-18 | Corvus Pharmaceuticals, Inc. | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients |
| NCT04464395 | phase1 | completed | 2020-07-01 | 2021-03-01 | Corvus Pharmaceuticals, Inc. | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients |
FDA applications (0)
This company has no applications containing this asset.